Hut 8 Corp vs Revvity Inc — how do they compare? Hut 8 Corp trades at $81.31 (market cap $9.82B), while Revvity Inc trades at $154.78 (market cap $16.98B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 11 Days and Revvity Inc for 12 Days on average.
| HUT | RVTY | |
|---|---|---|
Market Cap | $9.82B | $16.98B |
Volume | 10,272,678 | 1,456,900 |
Sector | Financials | Health |
52-Week High | $133.02 | $157.36 |
52-Week Low | $33.76 | $82.26 |
Typical Hold Time | 11 Days | 12 Days |
Enterprise Value | $17.25B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
HUT's stock trades at $80.25, down 10.13% over 24 hours, reflecting bearish technical signals amid weak financials. The company reported a net loss of $226.15 million for 2025, with negative cash flow from operations, though it secured a $1.07 billion credit facility to bolster liquidity. Analyst consensus remains strongly bullish with a $162.69 price target, driven by optimism around its AI infrastructure contracts.
The outlook hinges on HUT's ability to monetize its AI data center pipeline and achieve profitability. Key risks include persistent losses, high debt levels, and execution challenges in a competitive market. The stock offers high-reward potential if the company delivers on its growth strategy, but investors face significant downside if operational improvements falter.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →